EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Analysts

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given an average rating of "Buy" by the nine analysts that are covering the stock, Marketbeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have covered the stock in the last year is $28.00.

Several brokerages have weighed in on EYPT. Jefferies Financial Group began coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a "buy" rating and a $15.00 price target on the stock. Robert W. Baird cut their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a report on Monday, November 11th. JPMorgan Chase & Co. cut their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a report on Saturday, September 21st. Finally, Chardan Capital upped their price objective on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, November 8th.

EyePoint Pharmaceuticals Trading Up 7.2 %

EYPT stock opened at $8.95 on Friday. EyePoint Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $30.99. The business's fifty day moving average price is $9.77 and its 200 day moving average price is $9.57.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several large investors have recently made changes to their positions in EYPT. Ameritas Investment Partners Inc. boosted its stake in shares of EyePoint Pharmaceuticals by 44.0% in the first quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company's stock valued at $77,000 after purchasing an additional 1,136 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of EyePoint Pharmaceuticals by 68.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock valued at $82,000 after purchasing an additional 4,172 shares during the period. Greenwich Wealth Management LLC boosted its stake in shares of EyePoint Pharmaceuticals by 8.3% in the third quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company's stock valued at $93,000 after purchasing an additional 900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of EyePoint Pharmaceuticals by 271.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock valued at $95,000 after purchasing an additional 7,953 shares during the period. Finally, Cyndeo Wealth Partners LLC purchased a new position in shares of EyePoint Pharmaceuticals in the third quarter valued at $100,000. Institutional investors and hedge funds own 99.41% of the company's stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.